(Reuters) -The U.S. Food and Drug Administration’s staff on Wednesday raised concerns that it was unclear if Johnson & Johnson and Bristol Myers Squibb’s cancer cell therapies would be[...]
By using this site, you agree to the storage of cookies on your device for enhanced navigation, site analysis, and The TradingPub's marketing. Data sharing with social media platforms might occur based on the privacy choices you make on those platforms. For specifics, see our Privacy Policy.OkPrivacy policy
